NY-ESO-1 peptide vaccine [clinicaltrials_resource:f42263dfae5e4323aa7d59fd186b33ca]
Vaccine Therapy in Treating Patients With Refractory Metastatic Melanoma [clinicaltrials:NCT00020397]Vaccine Therapy and Sargramostim in Treating Patients With Soft Tissue Sarcoma [clinicaltrials:NCT00027911]Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma [clinicaltrials:NCT00037037]Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer [clinicaltrials:NCT00066729]Vaccine Therapy in Treating Patients With Transitional Cell Cancer of the Bladder [clinicaltrials:NCT00070070]Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma [clinicaltrials:NCT00079144]
intervention [clinicaltrials_vocabulary:intervention]
NY-ESO-1 peptide vaccine [clinicaltrials_resource:f42263dfae5e4323aa7d59fd186b33ca]
Bio2RDF identifier
f42263dfae5e4323aa7d59fd186b33ca
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:f42263dfae5e4323aa7d59fd186b33ca
intervention name [clinicaltrials_vocabulary:intervention-name]
NY-ESO-1 peptide vaccine
identifier
clinicaltrials_resource:f42263dfae5e4323aa7d59fd186b33ca
title
NY-ESO-1 peptide vaccine
@en
type
label
NY-ESO-1 peptide vaccine [clinicaltrials_resource:f42263dfae5e4323aa7d59fd186b33ca]
@en